Status:
ENROLLING_BY_INVITATION
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
Lead Sponsor:
Ningbo No. 1 Hospital
Conditions:
Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolically Healthy Obesity
Eligibility:
All Genders
18-100 years
Brief Summary
Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hype...
Eligibility Criteria
Inclusion
- Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024;
- Aged 18 years or older at baseline;
- Completed an abdominal ultrasound examination during the health check-up.
Exclusion
- Underweight status at baseline, defined as BMI \< 18.5 kg/m² ；
- Missing data on height, weight, or components of the metabolic syndrome ;
- Baseline diagnosis of MASLD or any other liver diseases
- Baseline diagnosis of hyperuricemia
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
17040 Patients enrolled
Trial Details
Trial ID
NCT07001865
Start Date
April 1 2025
End Date
December 31 2025
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang Province 315000 Recruiting
Ningbo, China